Sept 8: At the end of July, Citius Pharmaceuticals received a Complete Response Letter from the FDA pertaining to its Biologics License Application for Lymphir, an engineered IL-2-diphtheria toxin fusion protein intended to treat relapsed or refractory cutaneous T-cell lymphoma
Page load link Go to Top
PepT1 Transporter-Mediated Absorption: KPV utilizes the PepT1 transporter, highly expressed in intestinal epithelial cells, supporting its bioavailability
Explore GHK-Cu Therapy Individual pages and treatment availability: Educational information does not mean every peptide is available or appropriate for every patient
Rather than mimicking gut hormones to suppress appetite, it stimulates the pituitary gland to produce and release more natural growth hormone
The processes of peptide injection, reconstitution, and storage call for items like insulin syringes, sterile vials, and bacteriostatic water, among others